Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects

International Journal of Cardiology

Volumn 98, Issue 1, 2005, Pages 107-112

  Rodés Cabau, Josep ^a,b   Palacios, Andrés ^a   Palacio, Carles ^a   Girona, Josep ^a   Galve, Enrique ^a   Evangelista, Arturo ^a   Casaldáliga, Jaume ^a   Albert, Dipma ^a   Picó, Marta ^a   Soler Soler, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Amplatzer septal occluder; Atrial septal defects; Coagulation; Platelets

Indexed keywords

PADGEM PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; FEMALE; FLOW CYTOMETRY; HEART ATRIUM SEPTUM DEFECT; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; EMBOLIZATION, THERAPEUTIC; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 19944433054     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.03.022     Document Type: Article

References (40)

1. Ebeid M.R. Percutaneous catheter closure of secundum atrial septal defects: a review. J. Invasive Cardiol. 14:2002;25-31
2. Chessa M., Carminati M., Butera G., et al. Early and late complications associated with transcatheter occlusion of secundum atrial defect. J. Am. Coll. Cardiol. 39:2002;1061-1065
3. Berger F., Ewert P., Bjornstad P.G., et al. Transcatheter closure as standard treatment for most interatrial defects: experience in 200 patients treated with the Amplatzer Septal Occluder. Cardiol. Young. 9:1999;468-473
4. Losay J., Petit J., Lambert V., et al. Percutaneous closure with Amplatzer device is a safe and efficient alternative to surgery in adults with large atrial septal defects. Am. Heart J. 142:2001;544-548
5. Chan K.C., Godman M.J., Walsh K., Wilson K., Redington A., Gibbs J.L. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart. 82:1999;300-306
6. Dhillon R., Thanopoulos B., Tsaousis G., Triposkiadis F., Kyriakidis M., Redington A. Transcatheter closure of atrial septal defects in adults with the Amplatzer septal occluder. Heart. 82:1999;559-562
7. Du Z.D., Hijazi Z.M., Kleinman C.S., Silverman N.H., Larntz K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults. Results of a multicenter nonrandomized trial. J. Am. Coll. Cardiol. 39:2002;1836-1844
8. LaRosee K., Deutsch H.J., Schnabel P., Schneider C.A., Burkhard-Meier C., Hopp H.W. Thrombus formation after transcatheter closure of atrial septal defect. Am. J. Cardiol. 84:1999;356-359
9. Cooke J.C., Gelman J.S., Menahem S., Harper R.W. Thrombus on an ASD closure device: a call for caution. Heart Lung Circ. 9:2000;30-31
10. Gastmann O., Werner G.S., Babic U.U., Figulla H.R. Thrombus formation on transcatheter ASD occluder device in a patient with coagulation factor XII deficiency. Catheter. Cardiovasc. Diagn. 43:1998;81-83
11. Sievert H., Babic U.U., Hausdorf G., et al. Transcatheter closure of atrial septal defect and patent foramen ovale with the ASDOS device (a multi-institutional European trial). Am. J. Cardiol. 82:1998;1405-1413
12. Acar P., Aggoun Y., Abdel-Massiht T. Images in cardiology: thrombus after transcatheter closure of ASD with an Amplatzer septal occluder assessed by three dimensional echocardiographic reconstruction. Heart. 88:2002;52
13. Abrams C., Shattil S.J. Immunological detection of activated platelets in clinical disorders. Thromb. Haemost. 65:1991;467-473
14. Kamath S., Blann A.D., Lip G.Y.H. Platelet activation: assessment and quantification. Eur. Heart J. 22:2001;1561-1571
15. Teitel J.M., Bauer K.A., Lau H.K., Rosenberg R.D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 fragment and trombin/antithrombin complex. Blood. 59:1982;1086-1097
16. Masura J., Gavora P., Formaneck A., Hijazi Z.M. Transcatheter closure of secundum atrial septal defects using the new self-centering amplatzer septal occluder: initial human experience. Catheter. Cardiovasc. Diagn. 42:1997;388-393
17. Mardia K.V. Applications of some measures of multivariate skewness and kurtosis in testing normality and robustness studies. Sankhya, Ser. B. 36:1974;115-128
18. Brunner E., Domhof S., Langer F. Nonparametric analysis of longitudinal data in factorial experiments. 2002;Wiley, New York. 261 pp.
19. Rodés-Cabau J., Molina C., Serrano C., et al. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter. Cardiovasc. Interv. 60:2003;540-542
20. Lock J.E., Rome J.J., Davis R., et al. Transcatheter closure of atrial septal defects. Experimental studies. Circulation. 79:1989;1091-1099
21. Sharafuddin M.J.A., Gu X., Titus J.L., Urness M., Cervera-Ceballos J.J., Amplatz K. Transvenous closure of secundum atrial septal defects. Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation. 95:1997;2162-2168
22. Cenni E., Ciapetti G., Cervellati M., et al. Activation of the plasma coagulation system induced by some biomaterials. J. Biomed. Mater. Res. 31:1996;145-148
23. Cenni E., Arciola C.R., Ciapetti G., et al. Platelet and coagulation factor variations induced in vitro by polyethylene terephthalate (Dacron) coated with pyrolytic carbonl. Biomaterials. 16:1995;973-976
24. Makkar R., Litvack F., Eigler N., et al. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation. 95:1997;1015-1021
25. Olsen D.B., Unger F., Oster H., et al. Thrombus generation within the artificial heart. J. Thorac. Cardiovasc. Surg. 70:1975;248-255
26. Christy J.R., Maroseck K.W. Ultrasonic determination of clot deposition rates in a milk-based, in-vitro procedure for thrombogenicity assessment. J. Heart Valve Dis. 9:2000;379-388
27. Pernerstorfer T., Eichler H.G., Stohlawetz P., Speiser W., Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis. 155:2001;389-393
28. Chronos N.A., Wilson D.J., Janes S.L., Hutton R.A., Buller N.P., Goodal A.H. Aspirin does not affect the flow cytometryc detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. Clin. Sci. (Lond.). 87:1994;575-580
29. Pernerstorfer T., Stohlawetz P., Stummvoll G., et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br. J. Haematol. 102:1998;1229-1231
30. Klinkhardt U., Bauersachs R., Adams J., et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin. Pharmacol. Ther. 73:2003;232-241
31. Serebruany V., Cummings C., Malinin A., Steinbul S., Gurbel P. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. Am. Heart J. 142:2001;611-616
32. Becker R., Bovill E., Corrao J., et al. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction. J. Thromb. Thrombolysis. 1:1994;95-100
33. Wallen N.H., Ladjevardi M. Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood. Thromb. Res. 15:1998;189-194
34. Bozic M., Blinc A., Stegnar M. D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis. Thromb. Res. 108:2003;107-114
35. Li Y.H., Teng J.K., Tsai W.C., et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 33:1999;1543-1548
36. López Y., Paloma M.J., Rifón J., Cuesta B., Páramo J.A. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb. Res. 93:1999;71-78
37. Nakamura K., Toyohira H., Kariyazono H., Yamada K., Moriyama Y., Taira A. Relationship between changes in F1+2 and TAT levels and blood coagulation early after prosthetic valve replacement. Thromb. Res. 86:1997;161-171
38. Sohara H., Amitani S., Kurose M., Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J. Am. Coll. Cardiol. 29:1997;106-112
39. Bincardi M., Cimminiello C., Toschi V., et al. TAT, F1+2, and D-dimer levels in patients after coronary angiography with nonionic or ionic contrast media or after cardiac catheterization. Semin. Thromb. Hemost. 22:1996;61-65
40. Hafner G., Schinzel H., Ehrenthal W., et al. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1+2 and thrombin-antithrombin III complex. Ann. Hematol. 67:1993;121-125